

Correction

Correction: Dietary compound isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast cancer stem cells through WIF1 demethylation**Neng Wang^{1,*}, Zhiyu Wang^{1,2,*}, Yu Wang³, Xiaoming Xie⁴, Jiangan Shen¹, Cheng Peng⁵, Jieshu You¹, Fu Peng¹, Hailin Tang⁴, Xinyuan Guan⁶ and Jianping Chen^{1,5}**¹School of Chinese Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong²Department of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangdong, China³Department of Pharmacology, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong⁴Department of Breast Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, China⁵School of Pharmaceutical Science, Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu, China⁶Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong

*These authors contributed equally to this work

Published:**Copyright:** © 2021 Wang et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 5C, the 1st row, 2nd panel image within the MDA-MB-231 section is an accidental duplicate of the 1st row, 2nd panel image within the MCF-7 section. Also in Figure 5C, the 2nd row, 3rd panel image is an accidental duplicate of the 2nd row, 6th panel image in Figure 7E. In Figure 7A, the β -actin band in the ISL (25 μ M) section is an accidental duplicate of the β -actin band in the MDA-MB-231 section of Figure 6B. The corrected Figures 5C and 7A, produced from the original data, are shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2015; 6:9854–9876. <https://doi.org/10.18632/oncotarget.3396>




Figure 5: (C) Effects of ISL on the primary, secondary and tertiary mammospheres formed by the sorted CSCs from MDA-MB-231 and MCF-7 cells. The CSCs were incubated with or without ISL (10, 25 or 50 μM) for 7 days. The number and size of the mammospheres were determined using fluorescence microscopy (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ vs. negative control of the 1st passage spheres; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ vs. negative control of the 2nd passage spheres; ^ $P < 0.05$, ^^ $P < 0.01$, ^^ $P < 0.001$ vs. negative control of the 3rd passage spheres, values represented as the mean \pm SD, $n = 3$); the results showed that ISL administration could significantly limit the number and size of mammospheres formed by both CSCs populations.




Figure 7: (A) MDA-MB-231 cells treated with ISL at varying concentrations or time intervals were assayed by western blotting for β-catenin (cytoplasmic and nuclear) and ALDH1A3 antigen. β-actin and Lamin B were used as cytoplasmic and nuclear protein loading controls, respectively. The results indicated that ISL administration inhibits ALDH1A3 and β-catenin expression in a dose-and time-dependent manner.